When to Increase Jardiance Dose
Increase Jardiance from 10 mg to 25 mg once daily if additional glycemic control is needed in patients tolerating the initial dose. 1
Dosing Algorithm
Initial Dosing
- Start with 10 mg once daily in the morning, with or without food 1
- Assess renal function before initiating (must have eGFR ≥20 mL/min/1.73 m²) 1
- Correct volume depletion before starting 1
When to Consider Dose Escalation
Increase to 25 mg once daily if:
- Patient tolerates 10 mg without adverse effects
- Additional glycemic control is needed (HbA1c not at goal)
- No contraindications have developed 1
The FDA label is explicit that dose escalation is specifically for additional glycemic control in tolerating patients. This is the primary indication for increasing the dose.
Evidence Supporting Dose Escalation
Glycemic efficacy improves with higher doses:
- 10 mg reduces HbA1c by 0.48-0.73%
- 25 mg reduces HbA1c by 0.59-0.84% 2
- Network meta-analysis shows 25 mg performs best when considering HbA1c, fasting glucose, and adverse events together 3
- 35-60% of patients achieve HbA1c <7%, with higher rates at 25 mg 2
The 25 mg dose maintains cardiovascular and renal benefits seen in major trials (EMPA-REG OUTCOME used both 10 and 25 mg doses) 2
Important Caveats
Do NOT increase dose for:
- Cardiovascular or renal protection alone - both 10 mg and 25 mg provide these benefits; the increase is specifically for glycemic control 4, 2
- Patients with eGFR <20 mL/min/1.73 m² - insufficient data to support any dosing 1
- Patients on dialysis - contraindicated 1
Timing Considerations
- Glucose-lowering effect is minimal at eGFR <45 mL/min/1.73 m², but continue for cardiovascular and kidney benefit until dialysis 4
- Effects are sustained over time - studies show maintained efficacy at 76-78 weeks 5, 6
- Urinary glucose excretion plateaus by day 3-5 after dose changes 1
Safety Profile
- Adverse event rates are similar between 10 mg and 25 mg (60.9-63.9% vs 64% placebo) 7
- Genital infections slightly higher with dose escalation (3.5-4.6% vs 1% placebo) 7
- Volume depletion risk remains low but monitor blood pressure and renal function 4
- Hypoglycemia risk minimal unless combined with insulin or sulfonylureas 2
The decision to increase is straightforward: if the patient needs better glucose control and tolerates 10 mg, escalate to 25 mg. There is no need to wait a specific duration on 10 mg before increasing, though clinical trials typically assessed efficacy at 12-24 weeks.